FCF Biotech Venture Capital Monitor – USA 12/2022 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 12/2022”.

The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector.

As of the end of  December 2022, we identify the following current VC trends in the US-Biotech sector:

  • In 2022, overall Biotech funding in the USA has reached USD 31,894m (-1,027m compared to 2021)
  • The top 5 deals exceed USD 340m each, largest transaction amounted to USD 3,000m in Altos Labs
  • ARCH Venture Partners (USA) is leading the Top 5 Investors (by deal volume), followed by OrbiMed (USA) and RA Capital Management (USA)
  • Oncology dominates as the top indication

To access the full report, please click here.

By Dr. Mathias Schott, Johannes Link and Marcel-Louis Christou.